Isomorphic Labs Raises $2.1 Billion for AI Drug Discovery
Isomorphic Labs, a Google DeepMind spinout led by Demis Hassabis, secured $2.1 billion in Series B funding to accelerate AI-driven drug discovery. Led by Thrive Capital with participation from Alphabet, MGX, and Temasek, the investment supports scaling its AlphaFold-based platform. The company aims to initiate clinical trials by late 2026, slightly delaying previous targets. This significant capital injection highlights growing investor confidence in applying artificial intelligence to pharmaceutical development, positioning Isomorphic Labs as a major competitor in transforming traditional drug design processes through advanced computational biology.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Alphabet's Isomorphic Labs Raises $2.1 Billion to Advance AI-Designed Drugs
Isomorphic Labs, the artificial intelligence-focused drug discovery spinout from Alphabet Inc., has successfully secured $2.1 billion in Series B funding. This significant capital injection is strategically designated to accelerate the expansion of its pharmaceutical pipeline and propel various AI-designed drug candidates toward clinical trials by the end of 2026. The fundraising round underscores the growing intersection of technology and healthcare, highlighting investor confidence in leveraging advanced machine learning models to revolutionize traditional drug development processes. By integrating AlphaFold technology and other proprietary AI systems, Isomorphic Labs aims to drastically reduce the time and cost associated with identifying viable therapeutic targets. This move positions the company as a major competitor in the biotech sector, challenging established pharmaceutical giants with data-driven approaches. The announcement reflects a broader trend where tech conglomerates are increasingly investing in life sciences to solve complex biological problems. As the company prepares for upcoming clinical phases, this financial backing provides the necessary resources to scale operations, hire top talent, and conduct rigorous testing, potentially bringing novel treatments to market faster than conventional methods allow.
QuartzGoogle AI Legend Demis Hassabis Raises Capital for Drug Discovery Startup Isomorphic Labs
Demis Hassabis, the renowned co-founder and CEO of Google’s DeepMind artificial intelligence laboratory, has successfully secured significant funding for his new venture, Isomorphic Labs. This startup, which spun out from DeepMind, is dedicated to leveraging advanced artificial intelligence technologies to revolutionize the pharmaceutical industry. The primary objective of Isomorphic Labs is to accelerate the discovery and creation of new drugs, a process that is traditionally time-consuming and expensive. By applying cutting-edge AI models, the company aims to streamline drug development pipelines, potentially bringing life-saving treatments to market more efficiently. This development highlights the growing intersection of technology and healthcare, showcasing how major tech figures are expanding their influence into biological sciences. The fundraising effort underscores investor confidence in the potential of AI-driven solutions to solve complex biological problems. As a leader in the AI field, Hassabis's move signals a strategic shift towards applying deep learning capabilities specifically to molecular biology and drug design, marking a significant milestone in the commercial application of AI for health innovations.
MarketWatch.com - Top StoriesIsomorphic Labs Raises $2.1 Billion in Funding Led by Thrive
Isomorphic Labs, a prominent artificial intelligence-driven drug discovery company and spinoff from Google DeepMind, has successfully secured $2.1 billion in a new funding round. This significant financial injection was led by the investment firm Thrive. The latest fundraising effort follows the company's initial round in March 2025, where it raised $600 million, demonstrating strong investor confidence in its AI-powered approach to pharmaceutical development. Announced on Wednesday, May 12, 2026, this capital raise underscores the growing intersection of advanced artificial intelligence and biotechnology. Isomorphic Labs aims to utilize these funds to accelerate its research capabilities, potentially transforming traditional drug discovery processes through machine learning algorithms. The substantial increase in valuation from its previous round highlights the market's enthusiasm for AI applications in healthcare and life sciences. This event marks a major milestone for the company as it continues to expand its operational scale and technological infrastructure. The involvement of Thrive as the lead investor signals strategic backing for Isomorphic Labs' mission to leverage deep learning for identifying novel therapeutic targets and accelerating the creation of new medicines.
TechmemeGoogle-backed Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery
Isomorphic Labs, an artificial intelligence-driven drug discovery company spun off from Google DeepMind, has successfully raised $2.1 billion in its latest funding round. The investment was led by existing backer Thrive Capital and included participation from Google Ventures, Alphabet, MGX, Temasek, and CapitalG. Although the valuation remains undisclosed, this significant capital injection aims to scale the company's drug design engine and accelerate the application of AI in healthcare. Founder and CEO Demis Hassabis stated that the funds will support their mission to solve all diseases by leveraging technology rooted in breakthroughs like AlphaFold, which predicts protein structures. Consequently, the company has adjusted its timeline, now expecting to initiate its first clinical trials by the end of 2026, a delay from the previously targeted 2025 date. This development highlights the growing industry focus on utilizing AI to shorten drug discovery timelines and enhance research efficiency. Based in London, Isomorphic Labs previously raised $600 million in its initial funding round, underscoring continued investor confidence in its potential to transform pharmaceutical development through advanced computational biology and machine learning technologies.
Latest NewsDeepMind Spinout Isomorphic Labs Raises $2.1 Billion in Series B Funding
Isomorphic Labs, a spinout from Google DeepMind focused on AI-driven drug discovery, has successfully raised $2.1 billion in a Series B funding round. The investment was led by US venture firm Thrive Capital, with significant participation from the UK’s Sovereign AI fund, Abu Dhabi’s MGX, Alphabet’s GV, and Singapore’s Temasek. This substantial capital injection follows a $600 million raise completed just one year prior. Founded in 2021 by DeepMind CEO Demis Hassabis and company president Colin Murdoch, Isomorphic Labs leverages the groundbreaking AlphaFold technology to predict protein structures and accelerate pharmaceutical development. The decision to spin out from DeepMind was driven by the need for a specialized workforce comprising chemists, biologists, and pharmacologists, distinct from DeepMind’s core engineering focus. The company has already established partnerships with major pharmaceutical giants like Eli Lilly and Novartis. While earlier reports suggested entry into clinical trials by late 2025, recent clarifications indicate that pre-clinical trials have commenced. This funding underscores the growing intersection of artificial intelligence and life sciences, positioning Isomorphic Labs as a key competitor against other tech firms entering the healthcare sector.
Sifted